With up to 50%
odds of recurrence
within 1 year of treatment..., high-risk NMIBC
has high stakes.1,2*

...high-risk NMIBC
has high stakes.1,2*

*Based on a combined analysis of individual patient data from
7 EORTC clinical trials including 2,596 patients. All of the included
studies evaluated patients post-TURBT, at which point they received
variable treatments.1

EORTC, European Organisation for Research and Treatment of Cancer; NMIBC, non-muscle–invasive bladder cancer; TURBT, transurethral resection of bladder tumor.

References: 1. Sylvester RJ, van der Meijden APM, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466-477. doi:10.1016/j.eururo.2005.12.031 2. Ritch CR, Velasquez MC, Kwon D, et al. Use and validation of the AUA/SUO risk grouping for nonmuscle invasive bladder cancer in a contemporary cohort. J Urol. 2020;203(3):505-511. doi:10.1097/JU.0000000000000593

©2025 Pfizer Inc. All rights reserved.
March 2025 PP-SSN-USA-0072

Learn more at the
Pfizer booth or visit HighRiskNMIBC.com